These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 16210138)

  • 1. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
    Kaczmarek I; Bigdeli AK; Vogeser M; Mueller T; Beiras-Fernandez A; Kaczmarek P; Schmoeckel M; Meiser B; Reichart B; Ueberfuhr P
    Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy.
    Filler G
    Transpl Int; 2004 Mar; 17(3):120-5. PubMed ID: 14749919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients.
    Solari SG; Goldberg LR; DeNofrio D; Shaw LM
    Ther Drug Monit; 2005 Aug; 27(4):417-21. PubMed ID: 16044096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation.
    Filler G
    Pediatr Transplant; 2006 Sep; 10(6):707-11. PubMed ID: 16911495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of mycophenolic acid in kidney transplant recipients treated with a low dose (1 gram/day) of mycophenolate mofetil.
    Julasareekul W; Eiam-Ong S; Bejraputra O; Seublinvong T
    J Med Assoc Thai; 2003 Aug; 86(8):766-71. PubMed ID: 12948276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children.
    Filler G; Feber J; Lepage N; Weiler G; Mai I
    Pediatr Transplant; 2002 Oct; 6(5):411-8. PubMed ID: 12390429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation.
    Langers P; Press RR; Inderson A; Cremers SC; den Hartigh J; Baranski AG; van Hoek B
    Ther Drug Monit; 2014 Apr; 36(2):141-7. PubMed ID: 24081208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U; Ullrich S; Roskos M; Misselwitz J
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients.
    Miura M; Satoh S; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Suzuki T
    Ther Drug Monit; 2008 Feb; 30(1):52-9. PubMed ID: 18223463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring.
    Ragette R; Kamler M; Weinreich G; Teschler H; Jakob H
    J Heart Lung Transplant; 2005 Sep; 24(9):1315-9. PubMed ID: 16143250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients.
    Frassetto LA; Tan-Tam CC; Barin B; Browne M; Wolfe AR; Stock PG; Roland M; Benet LZ
    Transplantation; 2014 Mar; 97(6):702-7. PubMed ID: 24389906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation.
    Wacke R; Kundt G; Gock M; Klar E; Drewelow B; Schareck W
    Transplant Proc; 2006 Apr; 38(3):751-2. PubMed ID: 16647462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.